Thomas TÃ¹/₄ting

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1027105/publications.pdf

Version: 2024-02-01

184 papers 12,601 citations

58 h-index 105 g-index

199 all docs 199 docs citations

times ranked

199

21526 citing authors

#	Article	lF	Citations
1	Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	15.2	823
2	Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature, 2014, 507, 109-113.	13.7	547
3	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature, 2012, 490, 412-416.	13.7	506
4	A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 2001, 93, 243-251.	2.3	353
5	5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	15.2	353
6	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. Immunity, 2013, 39, 482-495.	6.6	338
7	Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science, 2007, 316, 1494-1497.	6.0	302
8	Excitation-induced ataxin-3 aggregation in neurons from patients with Machado–Joseph disease. Nature, 2011, 480, 543-546.	13.7	282
9	The experimental power of FR900359 to study Gq-regulated biological processes. Nature Communications, 2015, 6, 10156.	5.8	282
10	Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature, 2019, 565, 366-371.	13.7	266
11	Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients. Journal of Clinical Oncology, 2006, 24, 1178-1187.	0.8	257
12	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. Nature Reviews Cancer, 2013, 13, 365-376.	12.8	242
13	Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, 2014, 4, 674-687.	7.7	226
14	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	6.6	207
15	Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. Journal of Pathology, 2005, 205, 435-442.	2.1	202
16	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature, 2017, 541, 233-236.	13.7	194
17	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes and Development, 2017, 31, 18-33.	2.7	184
18	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nature Communications, 2015, 6, 8755.	5.8	175

#	Article	IF	Citations
19	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. Cancer Cell, 2009, 16, 103-114.	7.7	163
20	Effective collaboration between marginal metallophilic macrophages and CD8 ⁺ dendritic cells in the generation of cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 216-221.	3.3	160
21	Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Therapy, 2000, 7, 2036-2040.	2.3	159
22	Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. European Journal of Immunology, 2006, 36, 12-20.	1.6	153
23	An IFN-Associated Cytotoxic Cellular Immune Response against Viral, Self-, or Tumor Antigens Is a Common Pathogenetic Feature in "Interface Dermatitis― Journal of Investigative Dermatology, 2008, 128, 2392-2402.	0.3	151
24	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Research, 2017, 77, 4697-4709.	0.4	126
25	Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. British Journal of Dermatology, 2005, 153, 157-162.	1.4	123
26	The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. British Journal of Dermatology, 2007, 157, 752-757.	1.4	120
27	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self― antigens induce antitumor immunityin vivo. European Journal of Immunology, 1997, 27, 2702-2707.	1.6	119
28	Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. British Journal of Dermatology, 2005, 153, 1011-1015.	1.4	114
29	Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clinical and Experimental Dermatology, 2006, 31, 576-582.	0.6	113
30	Evidence for a Pathophysiological Role of Keratinocyte-Derived Type III Interferon (IFNλ) in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2011, 131, 133-140.	0.3	110
31	Type I interferon-associated cytotoxic inflammation in lichen planus. Journal of Cutaneous Pathology, 2006, 33, 672-678.	0.7	107
32	Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. British Journal of Dermatology, 2005, 152, 258-264.	1.4	105
33	Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 698-711.	2.7	104
34	Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN- $\hat{1}\pm$ production. Journal of Gene Medicine, 2006, 8, 1300-1306.	1.4	99
35	Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma., 2000, 86, 89-94.		95
36	Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia, 2008, 22, 393-399.	3.3	94

#	Article	IF	CITATIONS
37	DNA Immunization Targeting the Skin: Molecular Control of Adaptive Immunity. Journal of Investigative Dermatology, 1998, 111, 183-188.	0.3	91
38	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	2.6	91
39	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncolmmunology, 2017, 6, e1320626.	2.1	89
40	Type I Interferon–Associated Recruitment of Cytotoxic Lymphocytes. American Journal of Clinical Pathology, 2005, 124, 37-48.	0.4	88
41	Loss-of-Function Mutations in the Filaggrin Gene and Alopecia Areata: Strong Risk Factor for a Severe Course of Disease in Patients Comorbid for Atopic Disease. Journal of Investigative Dermatology, 2007, 127, 2539-2543.	0.3	87
42	Direct targeting of Gα $<$ sub>q $<$ /sub> and Gα $<$ sub>11 $<$ /sub> oncoproteins in cancer cells. Science Signaling, 2019, 12, .	1.6	84
43	How neutrophils promote metastasis. Science, 2016, 352, 145-146.	6.0	81
44	Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. Gene Therapy, 2001, 8, 1255-1263.	2.3	80
45	IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs. Journal of Immunology, 2000, 164, 567-572.	0.4	79
46	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. British Journal of Dermatology, 2018, 178, 443-451.	1.4	78
47	Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. Nature Communications, 2016, 7, 13515.	5.8	74
48	Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Experimental Dermatology, 2007, 16, 454-463.	1.4	73
49	Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Therapy, 1999, 6, 45-53.	2.2	72
50	Interleukin-10-Treated Dendritic Cells Modulate Immune Responses of Naive and Sensitized T Cells In Vivo. Journal of Investigative Dermatology, 2002, 119, 836-841.	0.3	71
51	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy, 1999, 6, 73-80.	2.2	69
52	Gene Expression Profiling of Lichen Planus Reflects CXCL9+-Mediated Inflammation and Distinguishes this Disease from Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2008, 128, 67-78.	0.3	68
53	Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells. Cancer Research, 2017, 77, 291-302.	0.4	68
54	Gene-based strategies for the immunotherapy of cancer. Journal of Molecular Medicine, 1997, 75, 478-491.	1.7	67

#	Article	IF	CITATIONS
55	Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity, 2016, 44, 1406-1421.	6.6	67
56	Genomeâ€wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Experimental Dermatology, 2015, 24, 510-515.	1.4	66
57	Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. Journal of Gene Medicine, 1999, 1, 400-406.	1.4	65
58	Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Archives of Dermatological Research, 2000, 292, 437-445.	1.1	64
59	Role of the Chemokine Receptor CCR4 and its Ligand Thymus- and Activation-Regulated Chemokine/CCL17 for Lymphocyte Recruitment in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2005, 124, 1241-1248.	0.3	63
60	Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunology, Immunotherapy, 2006, 55, 246-253.	2.0	62
61	Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Archives of Dermatological Research, 2009, 301, 83-86.	1.1	62
62	Primary plasmacytoma of the skin. Journal of the American Academy of Dermatology, 1996, 34, 386-390.	0.6	61
63	Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Therapy, 2000, 7, 249-254.	2.3	61
64	Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. Cancer Research, 2006, 66, 5427-5435.	0.4	59
65	Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis. Trends in Immunology, 2016, 37, 364-374.	2.9	59
66	Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Research, 2008, 18, 346-352.	0.6	58
67	Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 994-1000.	2.7	58
68	Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Therapy, 2003, 10, 1035-1040.	2.3	55
69	Role of the Aryl Hydrocarbon Receptor in Environmentally Induced Skin Aging and Skin Carcinogenesis. International Journal of Molecular Sciences, 2019, 20, 6005.	1.8	55
70	Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clinical and Experimental Dermatology, 2005, 30, 702-706.	0.6	54
71	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. American Journal of Pathology, 2006, 169, 665-672.	1.9	53
72	Indoleamine 2,3-Dioxygenase (IDO). American Journal of Pathology, 2007, 171, 1936-1943.	1.9	52

#	Article	IF	CITATIONS
73	Differential role of cannabinoids in the pathogenesis of skin cancer. Life Sciences, 2015, 138, 35-40.	2.0	49
74	Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo. European Journal of Cell Biology, 2004, 83, 797-803.	1.6	48
75	A Cell-Permeable Inhibitor to Trap GÎ $\pm q$ Proteins in the Empty Pocket Conformation. Chemistry and Biology, 2014, 21, 890-902.	6.2	47
76	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. Cancer Research, 2009, 69, 6265-6274.	0.4	46
77	Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen \hat{I}^2 -galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Therapy, 1999, 6, 629-636.	2.3	45
78	Peripheral CD8+ T Cell Tolerance Against Melanocytic Self-Antigens in the Skin Is Regulated in Two Steps by CD4+ T Cells and Local Inflammation: Implications for the Pathophysiology of Vitiligo. Journal of Investigative Dermatology, 2005, 124, 144-150.	0.3	45
79	The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. British Journal of Dermatology, 2007, 158, 071119222739011-???.	1.4	45
80	Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus, 2010, 19, 1020-1028.	0.8	45
81	Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Therapy, 2002, 9, 208-213.	2.3	44
82	RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncolmmunology, 2016, 5, e1219827.	2.1	44
83	Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Therapy, 1997, 4, 1053-1060.	2.3	42
84	A stochastic model for immunotherapy of cancer. Scientific Reports, 2016, 6, 24169.	1.6	42
85	IP10/CXCL10 - CXCR3 Interaction: a Potential Self-recruiting Mechanism for Cytotoxic Lymphocytes in Lichen Sclerosus et Atrophicus. Acta Dermato-Venereologica, 2007, 87, 112-117.	0.6	41
86	Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation. Journal of Immunology, 2013, 190, 4929-4936.	0.4	41
87	Priming of T cells with aAd-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Therapy, 2003, 10, 243-250.	2.3	40
88	CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. Journal of the American Academy of Dermatology, 2007, 56, 648-650.	0.6	40
89	Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. European Journal of Immunology, 2011, 41, 3028-3039.	1.6	40
90	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology, 2020, 38, 2543-2551.	0.8	40

#	Article	IF	CITATIONS
91	The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Experimental Dermatology, 2005, 14, 454-459.	1.4	39
92	Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology, 2010, 51, 1430-1437.	3.6	38
93	The epidermal polarity protein Par3 is a non–cell autonomous suppressor of malignant melanoma. Journal of Experimental Medicine, 2017, 214, 339-358.	4.2	37
94	CXCR3 <-> ligand–mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. Journal of the American Academy of Dermatology, 2008, 58, 437-442.	0.6	36
95	Interferon- $\hat{l}\pm$ stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. British Journal of Dermatology, 2011, 165, 1118-1123.	1.4	36
96	Autochthonous primary and metastatic melanomas in Hgfâ€Cdk4 ^{R24C} mice evade Tâ€cellâ€mediated immune surveillance. Pigment Cell and Melanoma Research, 2010, 23, 649-660.	1.5	34
97	Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus, 2011, 20, 1300-1304.	0.8	34
98	Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clinical and Experimental Dermatology, 2012, 37, 139-142.	0.6	34
99	Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. British Journal of Dermatology, 2005, 153, 462-463.	1.4	33
100	The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. Journal of the American Academy of Dermatology, 2005, 53, 422-427.	0.6	33
101	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. Cancer Research, 2016, 76, 251-263.	0.4	33
102	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	0.8	33
103	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgfâ€Cdk4 ^{R24C} C57BL/6 mice. International Journal of Cancer, 2011, 129, 285-294.	2.3	32
104	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. Cancer Research, 2011, 71, 5827-5837.	0.4	31
105	RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation. Cancer Immunology Research, 2017, 5, 455-467.	1.6	29
106	Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. Journal of the American Academy of Dermatology, 2011, 64, 988-989.	0.6	28
107	"Glowing Head―Mice: A Genetic Tool Enabling Reliable Preclinical Image-Based Evaluation of Cancers in Immunocompetent Allografts. PLoS ONE, 2014, 9, e109956.	1.1	28
108	Transcriptional profiling identifies an interferonâ€associated host immune response in invasive squamous cell carcinoma of the skin. International Journal of Cancer, 2008, 123, 2605-2615.	2.3	27

#	Article	IF	CITATIONS
109	Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanateâ€induced mouse atopicâ€like dermatitis. Experimental Dermatology, 2014, 23, 401-406.	1.4	27
110	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. Stem Cells, 2016, 34, 832-846.	1.4	27
111	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity, 2020, 53, 564-580.e9.	6.6	27
112	Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Therapy, 1999, 6, 1988-1994.	2.3	26
113	Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. British Journal of Dermatology, 2006, 155, 861-862.	1.4	26
114	The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry inÂMelanoma Progression and Metastasis. Journal of Investigative Dermatology, 2016, 136, 372-377.	0.3	25
115	Treatment of Recalcitrant Dermatomyositis with Efalizumab. Acta Dermato-Venereologica, 2006, 86, 254-255.	0.6	24
116	Safety and Efficacy of Topically Applied Selected Cutibacterium acnes Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study. Acta Dermato-Venereologica, 2019, 99, 1253-1257.	0.6	24
117	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8+ T Lymphocytes. Cancer Research, 2004, 64, 8068-8076.	0.4	22
118	Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Therapy, 2006, 13, 318-325.	2.2	22
119	Evaluation of DNA vaccination with recombinant adenoviruses using bioluminescence imaging of antigen expression: impact of application routes and delivery with dendritic cells. Journal of Gene Medicine, 2006, 8, 1243-1250.	1.4	22
120	Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of type I allergy. Gene Therapy, 2002, 9, 147-156.	2.3	21
121	Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models. Cancer Immunology Research, 2018, 6, 1292-1300.	1.6	21
122	The aryl hydrocarbon receptor promotes inflammationâ€induced dedifferentiation and systemic metastatic spread of melanoma cells. International Journal of Cancer, 2020, 147, 2902-2913.	2.3	20
123	Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. British Journal of Dermatology, 2008, 159, 231-233.	1.4	18
124	Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine, 2011, 29, 2313-2321.	1.7	18
125	Early Adenoviral Gene Expression Mediates Immunosuppression by Transduced Dendritic Cell (DC): Implications for Immunotherapy Using Genetically Modified DC. Journal of Immunology, 2004, 172, 1524-1530.	0.4	17
126	Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity. Journal of Investigative Dermatology, 2015, 135, 1996-2004.	0.3	16

#	Article	IF	CITATIONS
127	Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (PrografTM). British Journal of Dermatology, 2004, 151, 927-928.	1.4	15
128	Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells. European Journal of Cell Biology, 2007, 86, 817-826.	1.6	15
129	Dickkopf-3 Contributes to the Regulation of Anti-Tumor Immune Responses by Mesenchymal Stem Cells. Frontiers in Immunology, 2015, 6, 645.	2.2	15
130	Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries. PLoS ONE, 2010, 5, e14137.	1.1	15
131	Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology, 2009, 49, 471-481.	3.6	13
132	Nitrosative stress: a hallmark of the junctional inflammation in cutaneous lupus erythematosus. Clinical and Experimental Dermatology, 2013, 38, 96-97.	0.6	13
133	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. Oncolmmunology, 2016, 5, e1078964.	2.1	13
134	Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis. Oncogene, 2017, 36, 5058-5067.	2.6	13
135	Successful Rituximab Treatment of Severe Pemphigus Vulgaris Resistant to Multiple Immunosuppressants. Acta Dermato-Venereologica, 2005, -1, 1-1.	0.6	12
136	Additional Her 2/neu gene copies in patients with Sézary syndrome. Leukemia Research, 2006, 30, 755-760.	0.4	12
137	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. International Journal of Cancer, 2006, 118, 373-380.	2.3	12
138	Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clinical and Experimental Dermatology, 2008, 33, 347-348.	0.6	12
139	Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects. Handbook of Experimental Pharmacology, 2008, , 201-220.	0.9	12
140	Î ² -Arrestin 2 Inhibits Proinflammatory Chemokine Production and Attenuates Contact Allergic Inflammation in the Skin. Journal of Investigative Dermatology, 2014, 134, 2131-2137.	0.3	12
141	XIAP promotes melanoma growth by inducing tumour neutrophil infiltration. EMBO Reports, 2022, 23, e53608.	2.0	12
142	Impact of p53-based immunization on primary chemically-induced tumors. International Journal of Cancer, 2005, 113, 961-970.	2.3	11
143	<scp>T</scp> cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. Pigment Cell and Melanoma Research, 2013, 26, 441-456.	1.5	11
144	Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. Journal of Immunological Methods, 2006, 308, 77-89.	0.6	10

#	Article	IF	Citations
145	Identification of a $17\hat{1}^2$ -hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide. Cancer Immunology, Immunotherapy, 2010, 59, 113-24.	2.0	9
146	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2019, 80, 1299-1307.e7.	0.6	8
147	Cannabinoid Receptor 2 Modulates Maturation of Dendritic Cells and Their Capacity to Induce Hapten-Induced Contact Hypersensitivity. International Journal of Molecular Sciences, 2020, 21, 475.	1.8	8
148	Pankreatische Pannikulitis mit Polyarthritis (PPPâ€Syndrom). JDDG - Journal of the German Society of Dermatology, 2019, 17, 546-548.	0.4	7
149	Tumor cell intrinsic Tollâ€like receptor 4 signaling promotes melanoma progression and metastatic dissemination. International Journal of Cancer, 2022, 150, 142-151.	2.3	7
150	Interferon- \hat{l} ± Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells. Journal of Interferon and Cytokine Research, 2009, 29, 145-160.	0.5	6
151	Biolistic DNA Vaccination Against Melanoma. Methods in Molecular Biology, 2013, 940, 317-337.	0.4	5
152	The myeloid cell type I IFN system promotes antitumor immunity over proâ€tumoral inflammation in cancer Tâ€cell therapy. Clinical and Translational Immunology, 2021, 10, e1276.	1.7	5
153	DNA Vaccines Targeting Dendritic Cells for the Immunotherapy of Cancer. Advances in Experimental Medicine and Biology, 1998, 451, 295-304.	0.8	5
154	The Immunology of DNA Vaccines. , 2000, 29, 37-64.		4
155	Multicentre study on standardisation of melanoma cell culture - an initiative of the German Melanoma Research Network. Pigment Cell and Melanoma Research, 2010, 23, 296-298.	1.5	4
156	Development of Dendritic Cell-Based Genetic Vaccines for Cancer. Advances in Experimental Medicine and Biology, 1997, 417, 511-518.	0.8	4
157	Detection of a multilineage mosaic NRAS mutation c.181C>A (p.Gln61Lys) in an individual with a complex congenital nevus syndrome. Pigment Cell and Melanoma Research, 2019, 32, 470-473.	1.5	3
158	Activated Hgf-Met Signaling Cooperates with Oncogenic BRAF to Drive Primary Cutaneous Melanomas and Angiotropic Lung Metastases in Mice. Journal of Investigative Dermatology, 2020, 140, 1410-1417.e2.	0.3	3
159	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. Oncogene, 2021, 40, 5567-5578.	2.6	3
160	Type I Interferon–Associated Recruitment of Cytotoxic LymphocytesA Common Mechanism in Regressive Melanocytic Lesions. , 0, .		3
161	Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. Melanoma Research, 2016, 26, 89-91.	0.6	2
162	Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4 R24C mice. Melanoma Research, 2018, 28, 76-78.	0.6	2

#	Article	IF	CITATIONS
163	Pancreatic panniculitis with polyarthritis (PPP syndrome). JDDG - Journal of the German Society of Dermatology, 2019, 17, 546-547.	0.4	2
164	Live or Let Die: T Cell Survival in Cancer Immunotherapy. Immunity, 2019, 50, 280-282.	6.6	2
165	Successful treatment of nonâ€uremic calciphylaxis with bisphosphonate. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1498-1500.	0.4	2
166	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	1.2	2
167	Particle-Mediated Gene Transfer into Dendritic Cells: A Novel Strategy for the Induction of Immune Responses against Tumor Antigens., 2000, 35, 27-47.		1
168	Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin. Dermatology, 2007, 215, 81-83.	0.9	1
169	Of swords and ploughshares: immunosurveillance and inflammation in melanoma. Pigment Cell and Melanoma Research, 2010, 23, 727-728.	1.5	1
170	Regulatory Role of Cannabinoids forÂSkin Barrier Functions and CutaneousÂInflammation. , 2017, , 543-549.		1
171	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. European Journal of Cancer, 2021, 143, 43-45.	1.3	1
172	Melanoma Model Systems., 2017,, 369-398.		1
173	CRISPitope: A generic platform to model target antigens for adoptive TÂcell transfer therapy in mouse tumor models. STAR Protocols, 2022, 3, 101038.	0.5	1
174	Dendritic cell-based therapy for cancer. European Journal of Cancer, 1997, 33, S21.	1.3	0
175	Adjuvant administration of plasmid DNA expressing IL-12 enhances the induction of anti-melanoma immune responses with plasmid DNA encoding the murine melanosomal protein TRP-2. Journal of Dermatological Science, 1998, 16, S14.	1.0	0
176	Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice. Journal of Gene Medicine, 2005, 7, 613-620.	1.4	0
177	PS1-030. Tyrosine kinase inhibitor SU6668 blocks the polyIC-induced IFN \hat{I} »-expression of keratinocytes: TBK1 as a potential drug-target for the treatment of cutaneous lupus erythematosus. Cytokine, 2011, 56, 24.	1.4	0
178	Die tumorimmunologische Revolution in der Behandlung des fortgeschrittenen Melanoms. JDDG - Journal of the German Society of Dermatology, 2016, 14, 655-656.	0.4	0
179	Melanoma Model Systems. , 2011, , 309-335.		0
180	Melanoma Vaccines., 2011,, 2212-2215.		0

#	Article	IF	CITATIONS
181	Melanoma Vaccines. , 2014, , 2713-2717.		0
182	Abstract 5596: Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration., 2017 ,,.		0
183	Systematic assessment of LCMV based vaccine vectors expressing melanocyte differentiation antigens in human in vitro assays and in mouse melanoma models Journal of Clinical Oncology, 2019, 37, e14299-e14299.	0.8	0
184	Melanoma Vaccines. , 0, , 1812-1815.		0